Germany-based Fresenius Kabi will buy Akorn Inc. for $34 a share, plus the assumption of roughly $450 million of debt, for a deal valued at $4.3 billion, the companies said Monday. The deal is expected to close by early 2018 and will add to Fresenius Group's earnings in 2018. Fresenius Kabi specializes in injectable medicine while Akorn is a generic drug maker. Shares of Akorn rose 0.4% after hours.
Copyright © 2017 MarketWatch, Inc.